FolioLanternBeta
RVMDRevolution Medicines, Inc.

Anthony Mancini

Chief Global Commercialization Officer at Revolution Medicines, Inc., as of Sep 28, 2026Sold $9.8M of stock in the past 12 months: 93% under a disclosed plan and 7% to cover taxes.

Updated Oct 15, 2026 from SEC filings · covers Oct 16, 2025 to Oct 15, 2026
190
shares held after the latest filing, Revolution Medicines, Inc.
Vested shares reported on Forms 3, 4 and 5 only. Not the insider's whole wealth.
71K
shares sold, past 12 months
9
days with sales
$3.6M
largest single day, Mar 25, 2026
1
company filed for

Share of stake sold at Revolution Medicines, Inc. is not shown: the holdings do not reconcile with the filings. Why

Selling by month

Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled
OctNovDecJanFebMar 2026: $3.6M under a disclosed planMarApr 2026: $413K under a disclosed planAprMay 2026: $481K under a disclosed planMayJun 2026: $720K to cover taxesJunJulAugSep 2026: $4.6M under a disclosed plan$4.6MSepOct

Pattern

What the filings show, past 12 months. Nothing here rates or predicts.

Roles from filings

Every company we track where this person has filed, newest filing first.

CompanyTitleFirst filingLatest filing
Revolution Medicines, Inc. (RVMD)Chief Global Commercialization OfficerMar 26, 2026Sep 28, 2026

Recent filings

The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.

This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.